CA2723999C - Pestivirus replicons providing an rna-based viral vector system - Google Patents

Pestivirus replicons providing an rna-based viral vector system Download PDF

Info

Publication number
CA2723999C
CA2723999C CA2723999A CA2723999A CA2723999C CA 2723999 C CA2723999 C CA 2723999C CA 2723999 A CA2723999 A CA 2723999A CA 2723999 A CA2723999 A CA 2723999A CA 2723999 C CA2723999 C CA 2723999C
Authority
CA
Canada
Prior art keywords
replicon
gene
csfv
pharmaceutical composition
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2723999A
Other languages
English (en)
French (fr)
Other versions
CA2723999A1 (en
Inventor
Jon Duri Tratschin
Nicolas Ruggli
Kenneth Charles Mccullough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut fur Virologie und Immunologie(ivi)
Original Assignee
Institut fur Virologie und Immunologie(ivi)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut fur Virologie und Immunologie(ivi) filed Critical Institut fur Virologie und Immunologie(ivi)
Publication of CA2723999A1 publication Critical patent/CA2723999A1/en
Application granted granted Critical
Publication of CA2723999C publication Critical patent/CA2723999C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2723999A 2008-06-04 2009-05-30 Pestivirus replicons providing an rna-based viral vector system Active CA2723999C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08010222.1 2008-06-04
EP08010222A EP2130912A1 (en) 2008-06-04 2008-06-04 Pestivirus replicons providing an RNA-based viral vector system
PCT/EP2009/003892 WO2009146867A1 (en) 2008-06-04 2009-05-30 Pestivirus replicons providing an rna-based viral vector system

Publications (2)

Publication Number Publication Date
CA2723999A1 CA2723999A1 (en) 2009-12-10
CA2723999C true CA2723999C (en) 2022-03-15

Family

ID=39967852

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723999A Active CA2723999C (en) 2008-06-04 2009-05-30 Pestivirus replicons providing an rna-based viral vector system

Country Status (5)

Country Link
US (2) US9249395B2 (cg-RX-API-DMAC7.html)
EP (2) EP2130912A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011521654A (cg-RX-API-DMAC7.html)
CA (1) CA2723999C (cg-RX-API-DMAC7.html)
WO (1) WO2009146867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
HRP20160805T1 (hr) 2010-07-06 2016-08-12 Glaxosmithkline Biologicals Sa Imuniziranje velikih sisavaca malim dozama rna
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
SI3981427T1 (sl) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals S.A. Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
US20130189351A1 (en) * 2010-08-31 2013-07-25 Novartis Ag Lipids suitable for liposomal delivery of protein coding rna
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
BR112014000236A2 (pt) * 2011-07-06 2017-02-14 Novartis Ag lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
US10022436B2 (en) 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
TWI808057B (zh) 2016-06-24 2023-07-11 瑞士商隆沙有限公司 可變直徑生物感測器容器及系統，在接種階段列及生產感測器中使用減少量之感測器生產醱酵產物之方法，及生物生產設施
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
FI4182297T3 (fi) 2020-07-16 2025-12-05 Acuitas Therapeutics Inc Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
US12129223B2 (en) 2021-12-16 2024-10-29 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4474015A1 (en) 2023-06-05 2024-12-11 Veterna Srl Noda-like rna-vaccine pharmacon and production and uses thereof
CN118955658A (zh) * 2024-07-26 2024-11-15 华南农业大学 一种重组猪瘟病毒Npro蛋白、抗猪瘟病毒Npro蛋白的多克隆抗体及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) * 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
EP1035205A1 (en) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US20030077251A1 (en) * 2001-05-23 2003-04-24 Nicolas Escriou Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
JP4664072B2 (ja) * 2002-08-13 2011-04-06 インターベツト・インターナシヨナル・ベー・ベー Ｃ及び／又はｅ１タンパク質を発現しないペスチウイルスのレプリコン及びワクチンに使用できる前記レプリコンを含む感染性ウイルス粒子
WO2004092386A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells
EP2366719B1 (en) * 2005-04-26 2018-02-21 Sandoz AG Process of production of a recombinant polypeptide by fusion with an autoprotease
KR101097547B1 (ko) * 2005-12-07 2011-12-22 화이자 프로덕츠 인크. 마킹된 소 바이러스성 설사 바이러스 백신
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system

Also Published As

Publication number Publication date
EP2297309A1 (en) 2011-03-23
WO2009146867A1 (en) 2009-12-10
US9670466B2 (en) 2017-06-06
US20160108372A1 (en) 2016-04-21
US9249395B2 (en) 2016-02-02
US20110189224A1 (en) 2011-08-04
EP2130912A1 (en) 2009-12-09
CA2723999A1 (en) 2009-12-10
JP2011521654A (ja) 2011-07-28

Similar Documents

Publication Publication Date Title
CA2723999C (en) Pestivirus replicons providing an rna-based viral vector system
US11389522B2 (en) Flavivirus and alpha virus virus-like particles (VLPS)
AU740961B2 (en) Chimeric flavivirus vaccines
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
WO1998037911A9 (en) Chimeric flavivirus vaccines
MX2007004662A (es) Terapia basada en levaduras para infeccion cronica por hepatitis c.
WO2008119827A1 (en) Transreplicase constructs
CN102076356A (zh) 减毒瘟病毒
CN105229153A (zh) 细菌人工染色体
CN101155826B (zh) 作为疫苗的复制缺陷型rna病毒
AU2005279303B2 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
CN101278042A (zh) 新型重组人丙型肝炎病毒样颗粒及其生产方法
Kim et al. Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
Meyers Check for updates Chapter 2 Self-Replicating RNA Derived from the Genomes of Positive-Strand RNA Viruses Gregor Meyers and Birke Andrea Tews
CZ20033288A3 (cs) Protivirové agens
HK1092049A (en) Chimeric flavivirus vaccines
HK1025743B (en) Chimeric flavivirus vaccines
HK1149708A (en) Chimeric flavivirus vaccines

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140319